Altered states: psilocybin for treatment-resistant depression
The Lancet Psychiatry May 17, 2016 DOI: 10.1016/s2215-0366(16)30087-6 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Anxiety Depression Psilocybin |
| Keywords | Depression economics Hallucinogen Medline Antidepressant |
| Citations | 13 |
Abstract
“Alice remained looking thoughtfully at the mushroom for a minute, trying to make out which were the two sides of it; and as it was perfectly round, she found this a very difficult question”. To resolve the issue, Alice ate the mushroom; in more recent times, however, experimentation with psilocybin-containing magic mushrooms has been strongly discouraged. In the UK, in 2005, magic mushrooms were classified as a Class A substance, with then Home Office Minister Paul Goggins commenting: “Magic mushrooms are a powerful hallucinogen and can cause real harm, especially to vulnerable people and those with mental health problems”.
Citations in the library
Cited by 13
- Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics May 1, 2019
- Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences October 15, 2017
- Psychedelics and music: neuroscience and therapeutic implications International Review of Psychiatry July 4, 2018
- Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study Frontiers in Psychology December 6, 2018
- Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions Frontiers in Psychology July 25, 2017
and 8 more in the library
Cites 5
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry April 5, 2016
- Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. Biological Psychiatry July 1, 2015
- Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic Journal of Psychopharmacology June 1, 2014